PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Internal Medicine, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia.\', \'Universitas Airlangga Hospital, Surabaya, East Java, 60115, Indonesia.\', \'Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia.\', \'Department of Anesthesiology and Reanimation, Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia.\', \'Faculty of Medicine, Airlangga University, Surabaya, East Java, 60132, Indonesia.\', \'Department of Internal Medicine, Faculty of Medicine, Brawijaya University, Malang, East Java, 65145, Indonesia.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.12688/f1000research.45046.1
?:hasPublicationType
?:journal
  • F1000Research
is ?:pmid of
?:pmid
?:pmid
  • 33763201
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.926
?:rankingScore_hIndex
  • 21
is ?:relation_isRelatedTo_publication of
?:title
  • Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all